HK1085140A1 - Pharmaceutical compositions and method of using levodopa and carbidopa - Google Patents

Pharmaceutical compositions and method of using levodopa and carbidopa

Info

Publication number
HK1085140A1
HK1085140A1 HK06107583.2A HK06107583A HK1085140A1 HK 1085140 A1 HK1085140 A1 HK 1085140A1 HK 06107583 A HK06107583 A HK 06107583A HK 1085140 A1 HK1085140 A1 HK 1085140A1
Authority
HK
Hong Kong
Prior art keywords
carbidopa
levodopa
pharmaceutical compositions
compositions
methods
Prior art date
Application number
HK06107583.2A
Other languages
English (en)
Inventor
Julius Remenar
Orn Almarsson
Anthony J Meehan
Zhong Zhang
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of HK1085140A1 publication Critical patent/HK1085140A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK06107583.2A 2003-08-29 2006-07-05 Pharmaceutical compositions and method of using levodopa and carbidopa HK1085140A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49925603P 2003-08-29 2003-08-29
US50555103P 2003-09-24 2003-09-24
US55986404P 2004-04-06 2004-04-06
US58644204P 2004-07-08 2004-07-08
PCT/US2004/027607 WO2005023185A2 (en) 2003-08-29 2004-08-26 Pharmaceutical compositions and method of using levodopa and carbidopa

Publications (1)

Publication Number Publication Date
HK1085140A1 true HK1085140A1 (en) 2006-08-18

Family

ID=34280054

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107583.2A HK1085140A1 (en) 2003-08-29 2006-07-05 Pharmaceutical compositions and method of using levodopa and carbidopa

Country Status (10)

Country Link
US (1) US20050070608A1 (de)
EP (1) EP1670450B8 (de)
JP (1) JP5160786B2 (de)
AT (1) ATE495739T1 (de)
AU (1) AU2004270174B2 (de)
CA (1) CA2536175C (de)
DE (1) DE602004031134D1 (de)
HK (1) HK1085140A1 (de)
MX (1) MXPA06002344A (de)
WO (1) WO2005023185A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20070027216A1 (en) * 2005-07-15 2007-02-01 Bridget Larson Novel hydrochloride salts of levodopa
KR20080078075A (ko) * 2005-12-20 2008-08-26 세레우사이언스 아베 하지 불안 증후군의 치료 및 진단을 위한 방법 및 조성물
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JP5631734B2 (ja) * 2007-04-06 2014-11-26 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 流体薬物を供給するためのシステム及び方法
US8377474B2 (en) * 2007-12-28 2013-02-19 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
AU2014202306B2 (en) * 2007-12-28 2016-09-08 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
LT2432454T (lt) * 2009-05-19 2017-07-10 Neuroderm Ltd Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui
NZ617025A (en) * 2009-09-18 2014-03-28 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
WO2013035053A2 (en) * 2011-09-09 2013-03-14 Kareus Therapeutics, Sa Novel conjugation-facilitated transport of drugs across blood brain barrier
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (de) 2013-10-07 2021-02-24 Impax Laboratories, LLC Mukoadhäsive levodopa-formulierungen mit gesteuerter freisetzung und/oder levodopa-ester und verwendungen davon
HRP20231716T1 (hr) * 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US10071069B2 (en) 2014-09-04 2018-09-11 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
KR102578476B1 (ko) * 2016-04-11 2023-09-13 유니버시티 오브 캔버라 레보도파, 항산화제 및 수성 담체를 포함하는 안과 조성물
EP4295909A2 (de) * 2016-04-20 2023-12-27 AbbVie Inc. Carbidopa und l-dopa-prodrugs und verfahren zur verwendung
EA201992685A1 (ru) * 2017-06-05 2020-06-05 Дизлин Фармасьютикалз Аб Раствор леводопы для инфузий
JP2021509676A (ja) * 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるレボドパ粉末の鼻腔内送達
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928431A (en) * 1972-07-14 1975-12-23 Medica Ab Oy Method of isolating L-dopa from a aqueous solution thereof
US4771073A (en) 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4829875A (en) * 1988-09-12 1989-05-16 Queen's University At Kingston Over-centre locking tool
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5881926A (en) * 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
IL143071A0 (en) * 1998-11-10 2002-04-21 Teva Pharma Dispersible compositions containing l-dopa ethyl ester
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
NZ533062A (en) * 2001-12-19 2006-03-31 Alza Corp Formulation and dosage form for the controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
DE602004031134D1 (de) 2011-03-03
AU2004270174B2 (en) 2010-05-20
CA2536175A1 (en) 2005-03-17
EP1670450B8 (de) 2011-03-23
JP2007504143A (ja) 2007-03-01
EP1670450B1 (de) 2011-01-19
EP1670450A4 (de) 2008-08-27
MXPA06002344A (es) 2006-05-19
US20050070608A1 (en) 2005-03-31
JP5160786B2 (ja) 2013-03-13
AU2004270174A1 (en) 2005-03-17
ATE495739T1 (de) 2011-02-15
WO2005023185A3 (en) 2005-05-19
CA2536175C (en) 2013-05-28
EP1670450A2 (de) 2006-06-21
WO2005023185A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2005041924A3 (en) Administration of levodopa and carbidopa
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
TW200637522A (en) Skin treatment articles and methods
RS20060320A (en) Substituted indazole-o-glucosides
TW200519202A (en) Modulation of eIF4E expression
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
HRP20041071A2 (en) Methods of treating hepatitis
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
RS91004A (en) Methods of treating ileus
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
TW200716088A (en) Formulations and methods for treating amyloidosis
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MY148276A (en) Long-term feed- elderly
GEP20247585B (en) Furoindazole derivatives
TW200509896A (en) Analeptic and drug combinations
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
HK1091816A1 (en) Diphenylurea derivatives and their use as chloride channel blockers
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF THE INVENTOR FROM ALMARSSON, OM TO ALMARSSON, ORN

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210826